QuantiFERON-TB Gold Plus Test as a parameter of Mycobacterium tuberculosis detection

Amila Abduzaimović, Sabina Mahmutović-Vranić, Velma Rebić, Mufida Aljičević, Kadrija Abduzaimović, Anes Jogunčić

Abstract


Background: Latent tuberculosis infection (LTBI) is a state of persist immune response to Mycobacterium tuberculosis (M. tuberculosis) antigens without any clinical evidence of active tuberculosis. A new progress and inovation in diagnostics of latent tuberculosis, more specific and susceptible than tuberculin skin test, are Interferon Gamma Release Assay, Quanti FERON-TB test, in vitro blood tests used to detect immune response to TB proteins, by measuring interferon gamma (IFN-γ( in whole blood from persons infected with M. tuberculosis. The aim of this retrospective study was to determinate the role of QuantiFERON-TB Gold Plus (QFT – Plus test) test in diagnostics of LTBI evaluating the results from inpatients and outpatiens.

Methods: This was a retrospective study where blood samples were collected from 1st of January to 31st of December 2016 in the Microbiological Laboratory of General Hospital Tesanj. Samples were performed from inpatients and outpatients in Zenica-Doboj Canton. Full blood from patients aged from 1 to 95 years was collected in four, special QFT plus blood test tubes and tested with QFT – Plus test.

Results: The study involved 159 patients who were tested with QFT-Plus test. Gender distribution of positive data (30.82 %) showed prevalence of males (59.18 %). The most common diagnosis of positive data was infiltratio pulmonum (49 %). Sensitivity of QFT – Plus test was 91.67 % and test showed specificity of 73.79 %.

Conclusion: Our research showed that QFT – Plus test can be helpful, as a supplement, but it can not be the main parameter in diagnostics of tuberculosis. If the test is positive, it is necessary to observe all other clinical findings to complete the diagnosis.


Full Text:

PDF

References


Chapman H, Lauzardo M. Advances in Diagnosis and Treatment of Latent Tuberculosis Infection. The Journal of the American Board of Family Medicine. 2014;27(5):704-712.

Dutta N, Karakousis P. Latent Tuberculosis Infection: Myths, Models, and Molecular Mechanisms. Microbiology and Molecular Biology Reviews. 2014;78(3):343-371.

World Health Organziation (2016) Global tuberculosis report 2016. http://www.who.int/tb/publications/global_report/en/

Su V, Yen Y, Pan S, Chuang P, Feng J, Chou K et al. Latent Tuberculosis Infection and the Risk of Subsequent Cancer. Medicine. 2016;95(4):e2352.

Houben R, Dodd P. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLOS Medicine. 2016;13(10):e1002152.

Ticac B, Mahmic J, Barac S, Rozmanic V. The use of an interferon gamma release assay (IGRA) in the immunodiagnosis of tuberculosis. Medicina Fluminensis. 2016;51(2):296-304.

Pai M, Rodrigues C. Management of latent tuberculosis infection: An evidence-based approach. Lung India. 2015;32(3):205.

Masoumi H, Alborzi A, Pourabbas B, Kalani M. QuantiFERON-TB Gold and Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Children. Iran J Med Sci. 2015;40(5):411-417.

Brodie, D. Lederer DJ, Gallardo JS, Trivedi SH, Burzynski JN, Schluger NW. Use of an interferon-gamma release assay to diagnose latent tuberculosis infection in foreign-born patients. Chest.133, 869–874 (2008).

Mardani M, Abtahian Z. New Advances in Diagnosis of Latent Tuberculosis Infection: A Review Article. Archives of Pediatric Infectious Diseases. 2015;2(3).

Bothamley, G. H. IFN-gamma-release assays in the management of tuberculosis. Expert. Rev. Respir. Med. 1, 365–375 (2007).

Stagg H, Zenner D, Harris R, Muñoz L, Lipman M, Abubakar I. Treatment of Latent Tuberculosis Infection. Annals of Internal Medicine. 2014;161(6):419.

QuantiFERON [Internet]. Quantiferon.com. 2017 [cited 26 September 2017]. Available from: http://www.quantiferon.com/

Sultan B, Benn P, Mahungu T, Young M, Mercey D, Morris-Jones S et al. Comparison of two interferon-gamma release assays (QuantiFERON-TB Gold In-Tube and T-SPOT.TB) in testing for latent tuberculosis infection among HIV-infected adults. International Journal of STD & AIDS. 2013;24(10):775-779.

Blandinières A, de Lauzanne A, Guérin-El Khourouj V, Gourgouillon N, See H, Pédron B et al. QuantiFERON to diagnose infection by Mycobacterium tuberculosis: Performance in infants and older children. Journal of Infection. 2013;67(5):391-398.

Neyrolles O, Quintana-Murci L. Sexual Inequality in Tuberculosis. PLoS Medicine. 2009;6(12):e1000199.

Jimenez-Corona M. Gender differentials of pulmonary tuberculosis transmission and reactivation in an endemic area. Thorax. 2006;61(4):348-353.

Yi L, Sasaki Y, Nagai H, Ishikawa S, Takamori M, Sakashita K et al. Evaluation of QuantiFERON-TB Gold Plus for Detection of Mycobacterium tuberculosis infection in Japan. Scientific Reports. 2016;6(1).

Cruz-Hervert L, Garcia-Garcia L, Ferreyra-Reyes L, Bobadilla-del-Valle M, Cano-Arellano B, Canizales-Quintero S et al. Tuberculosis in ageing: high rates, complex diagnosis and poor clinical outcomes. Age and Ageing. 2012;41(4):488-495.

Rajagopalan S. Tuberculosis and Aging: A Global Health Problem. Clinical Infectious Diseases. 2001;33(7):1034-1039.

Mazurak G, Jereb J, LoBue P, Iademarco M, Metchock B, Vernon A. Guidelines for Using the QuantiFERON®-TB Gold Test for Detecting Mycobacterium tuberculosis Infection, United States. CDC. 2005;(54):49-55.

Takasaki J, Manabe T, Morino E, Muto Y, Hashimoto M, Iikura M et al. Sensitivity and specificity of QuantiFERON-TB Gold Plus compared with QuantiFERON-TB Gold In-Tube and T-SPOT.TB on active tuberculosis in Japan. Journal of Infection and Chemotherapy. 2017.

Hoffmann H, Avsar K, Göres R, Mavi S, Hofmann-Thiel S. Equal sensitivity of the new generation QuantiFERON-TB Gold plus in direct comparison with the previous test version QuantiFERON-TB Gold IT. Clinical Microbiology and Infection. 2016;22(8):701-703.


Refbacks

  • There are currently no refbacks.